viewChembio Diagnostics

Chembio reports narrower-than-estimated Q3 loss; shares gain

The provider of rapid point-of-care diagnostic tests reported better-than-expected quarterly revenue.

Chembio shares have gained 37% this year so far.

Chembio Diagnostics (NASDAQ:CEMI) rose in morning trading after the provider of rapid point-of-care diagnostic tests reported a narrower-than-expected quarterly loss and higher-than-estimated revenue.

Shares gained 1.5% to $5.34 at 10:58 a.m. in New York.

Net loss expanded to $0.4mln, or $0.05 loss per diluted share, in the September quarter, from  net loss of $0.3mln, or $0.03 loss per diluted share, the Medford, New York-based company said in a statement on Thursday.

That result beat the $0.07 loss estimated by one analyst polled by Capital IQ.

Third-quarter revenue  decreased 5.8% to $6.89mln, but topped the $6.65mln estimate of two analysts on average.

“Chembio continues to focus on the following three business areas: Sexually Transmitted Diseases (“STD”), Fever Diseases, and Technology Collaborations," chief executive officer John Sperzel said in the statement.

Quick facts: Chembio Diagnostics

Price: 5.77 USD

Market: NASDAQ
Market Cap: $116.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Archer Materials secures first patent for its quantum computing chip

Archer Materials Ltd's (ASX:AXE) CEO Dr Mohammad Choucair talks Proactive's Andrew Scott through the significance of being granted a Japanese patent for their quantum computing chip technology. It's the first granted patent protecting the chip and represents a significant commercial milestone in...

13 hours, 49 minutes ago

2 min read